3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Sarah Groen of Bell & Bly Travel, Alex Reed of Fluence Analytics, and Bettina Beech of UH. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from travel to analytics— recently making headlines in Houston innovation.

Sarah Groen, founder of Bell and Bly Travel

Sarah Groen, travel entrepreneur and longtime Houston tech ecosystem member, joins the Houston Innovators Podcast. Photo courtesy of Bell and Bly Travel

It's been a scary time for travel-related businesses, and Sarah Groen has had to get innovative to maintain her business as a travel adviser. Lucky for Groen, who has a long career in tech and innovation, she had all the right pivots, including offering digital travel packages, launching a new podcast, and more.

"During COVID, a lot of businesses either shutdown or took a pause, but we accelerated," Groen says.

Groen her career on the Houston Innovators Podcast. She also gives some strategic advice for founders — like trusting your gut and reading the signs when it comes to product-market fit — on the podcast. Click here to read more and stream the episode.

Alex Reed, co-founder and CEO of Fluence Analytics

Alex Reed joined InnovationMap for a Q&A on the company's move to Houston and its growth plans. Photo courtesy of Fluence Analytics

Alex Reed watched his father work in the labs on his research as he grew up, but he realized his future wasn't in the lab. Instead, he launched a career in taking that research and turning it into a company.

Founded in 2012 in New Orleans, Fluence Analytics has entered its next phase of growth by moving its headquarters to Houston following a $7.5 million venture capital raise.

We're working with the Houston of today, but also the Houston of tomorrow," Reed tells InnovationMap in a Q&A. Click here to read more.

Bettina Beech, chief population health officer at the University of Houston

Bettina Beech is a newly named AIM-AHEAD coordinating center team member. Photo via UH.edu

The University of Houston has joined in on a national initiative to increase the diversity of artificial intelligence researchers, according to a news release from the school. Unfortunately, AI — designed by humans — mimics human decision making through its choice of algorithms. This means that the same biases humans deal with have made it into the AI decision making too. These gaps can lead to continued disparities and inequities for underrepresented communities especially in regards to health care, job hiring, and more.

"Beyond health care, AI has been used in areas from facial recognition to self-driving cars and beyond, but there is an extreme lack of diversity among the developers of AI/ML tools. Many studies have shown that flawed AI systems and algorithms perpetuate gender and racial biases and have resulted in untoward outcomes," says Bettina Beech, chief population health officer at the University of Houston and newly named AIM-AHEAD coordinating center team member.

The initiative will bring together collaborators and experts across AI and machine learning, health equity research, data science training, data infrastructure and more. The other universities involved include: University of Colorado-Anschutz Medical Center in Aurora; University of California, Los Angeles; Meharry Medical College in Nashville; Morehouse School of Medicine in Atlanta; Johns Hopkins University, and Vanderbilt University Medical Center. Click here to read more.

Sarah Groen, travel entrepreneur and longtime Houston tech ecosystem member, joins the Houston Innovators Podcast. Photo courtesy of Bell and Bly Travel

Innovative travel adviser talks Houston tech and advice for female founders

houston innovators podcast episode 104

When the pandemic hit, it's safe to say that everyone in the travel industry panicked. Sarah Groen, who founded her company Bell and Bly Travel in 2017, caters her expertise to planning luxury travel experiences, and she didn't want her clients to forget about her expertise as the uncertainty of the pandemic continued. So, she got creative.

"Every single client who had a trip canceled, we sent them a digital package to help them feel like they were traveling," Groen says on this week's episode of the Houston Innovators Podcast. For example, if a client's trip to Italy canceled, Groen and her staff provided links to recipes of Italian dishes, virtual museum tours, and more.

"We didn't make money on that," Groen says. "We spent money to be able to have the bandwidth to be able to do that for our clients."

It's during this time thar Groen also launched her podcast, Luxury Travel Insider, where she gathers experts to discuss destinations.

It's these innovative endeavors that put Groen and Bell and Bly Travel on the map for Virtuoso's award — which Groen describes as the Oscars of the travel industry. She took home the title of "most innovative travel advisor" at the 2021 awards.

"During COVID, a lot of businesses either shutdown or took a pause, but we accelerated," Groen says.

The award is incredibly special to Groen she says especially to her background in tech. A native Houstonian, Groen went to the West Coast for her education. Despite loving her hometown, she says she returned kicking and screaming because she wanted to do something entrepreneurial, and Houston didn't yet have much to speak of in terms of a startup ecosystem.

So, like any good entrepreneur who sees a need in the market, she did it herself and co-founded Surge, an energy-focused accelerator. But it was a struggle to get momentum.

"But at that time, we couldn't even get the mayor to pay attention to us. We had people applying to our program and moving their companies from other cities and countries in some cases," Groen says. "But I think Surge starting was a big turning point."

Surge — which was co-founded by Kirk Coburn, who now is the investment director for Shell Ventures — officially shut down in 2016.

But things have changed within the Houston innovation ecosystem, and Groen discusses the transformation as she's observed it on the show. She also gives some strategic advice for founders — like trusting your gut and reading the signs when it comes to product-market fit — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings